老澳门六合彩图库

header-logo
GettyImages-609179959-hero
Hematology and Oncology
Fumou Sun, PhD

Fumou Sun, PhD

Assistant Professor

Locations

  • TBRC 4885
    Hematology and Oncology 鈥� Medicine
    Discovery & Developmental Therapeutics, Cancer Center

Contact Information

Education

PhD, Microbiological and Biochemical Pharmacy, China Pharmaceutical University, Nanjing, 2019

Biography

Dr. Sun is an Assistant Professor of medicine at the 老澳门六合彩图库, Division of Hematology and Oncology. Dr. Sun’s research interests focus on tumor immunotherapy, particularly the novel Chimeric Antigen Receptor T Cell (CAR-T) and multifunctional antibody therapies.

Dr. Sun earned his PhD from China Pharmaceutical University in 2019 and spent several years conducting advanced research in tumor genetics and immunotherapy at the University of Iowa, the 老澳门六合彩图库 (老澳门六合彩图库), and the University of Arkansas for Medical Sciences. In 2024, Dr. Sun returned to 老澳门六合彩图库, where he collaborates closely with clinical colleagues to advance the clinical applications of tumor immunotherapy.

Dr. Sun leads multiple funded projects and holds several patent applications. His research has been published in over 30 high-impact journals, including The Journal of Clinical Investigation (JCI), Nature Communications, and Cancer Research. He has received numerous prestigious awards, such as the 24th Annual ECOG-ACRIN Young Investigator Award, the American Society of Hematology (ASH) Abstract Achievement Awards in 2022 and 2023, the Young Investigator Award at the 17th International Myeloma Workshop (IMW) of the International Myeloma Society, and the Scholar-in-Training Award at the AACR Annual Meeting.

Research Interests

  • Immunotherapy
  • Chimeric Antigen Receptor T Cell Therapy
  • Chimeric Antigen Receptor NK Cell Therapy
  • Multifunctional Antibody Therapy
  • Oncolytic Virus Therapy
  • Hematologic Malignancies
  • Solid Tumors

Dr. Sun is dedicated to research in the field of tumor immunotherapy, particularly focusing on the development and application of novel Chimeric Antigen Receptor T Cell (CAR-T) immunotherapies. His research focuses on enhancing the therapeutic efficacy of CAR-T cells in treating relapsed and refractory tumors, as well as uncovering the molecular mechanisms underlying therapy resistance.

In addition, Dr. Sun is actively developing combinatory strategies involving CAR-T cells and oncolytic viruses to overcome the challenges associated with solid tumor treatment. He is also committed to innovating multifunctional antibody therapies, aiming to broaden the versatility of antibody-based treatments such as antibody-drug conjugates (ADCs) and bispecific antibodies.

Publications

  • (Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F.) Blood Cancer J. 2024 Nov 06;14(1):194 PMID: 39505839 PMCID: PMC11541562 11/07/2024

  • (Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C.) Blood Cancer J. 2024 Mar 06;14(1):38 PMID: 38443358 PMCID: PMC10915134 SCOPUS ID: 2-s2.0-85186929795 03/06/2024

  • (Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD Jr, Zhan F.) Nat Commun. 2024 Jan 19;15(1):615 PMID: 38242888 PMCID: PMC10798961 SCOPUS ID: 2-s2.0-85182665152 01/20/2024

  • (Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F.) J Clin Invest. 2024 Jan 02;134(1) PMID: 37883186 PMCID: PMC10760955 10/26/2023

  • (Pisano MD, Sun F, Cheng Y, Parashar D, Zhou V, Jing X, Sompallae R, Abrudan J, Zimmermann MT, Mathison A, Janz S, Pufall MA.) Haematologica. 2023 Dec 01;108(12):3372-3383 PMID: 37439384 PMCID: PMC10690922 SCOPUS ID: 2-s2.0-85178652041 07/13/2023

  • (Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD Jr, Zhan F.) Cell Rep Med. 2023 Oct 17;4(10):101214 PMID: 37794587 PMCID: PMC10591052 SCOPUS ID: 2-s2.0-85173718596 10/05/2023

  • (Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F.) J Hematol Oncol. 2023 Jun 29;16(1):70 PMID: 37386588 PMCID: PMC10308756 SCOPUS ID: 2-s2.0-85163879552 06/30/2023

  • (Pan M, Wang F, Nan L, Yang S, Qi J, Xie J, Shao S, Zou H, Wang M, Sun F, Zhang J.) Cancer Immunol Immunother. 2023 Apr;72(4):969-984 PMID: 36227341 PMCID: PMC10991987 10/14/2022

  • (Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F.) J Clin Invest. 2022 Sep 15;132(18) PMID: 35881476 PMCID: PMC9479617 07/27/2022

  • (Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S.) Oncogene. 2022 Aug;41(32):3899-3911 PMID: 35794249 PMCID: PMC9355869 SCOPUS ID: 2-s2.0-85133568311 07/07/2022

  • (Sun X, Pisano M, Xu L, Sun F, Xu J, Zheng W, Liu X, Zhang Y, Sun R, Cui X.) Sci Rep. 2022 Apr 21;12(1):6551 PMID: 35449393 PMCID: PMC9023573 04/23/2022

  • (Shi Y, Sun F, Cheng Y, Holmes B, Dhakal B, Gera JF, Janz S, Lichtenstein A.) Mol Cancer Ther. 2022 Apr 01;21(4):502-510 PMID: 35086951 PMCID: PMC8983490 SCOPUS ID: 2-s2.0-85128145497 01/29/2022

Publications of from the

© 2024 老澳门六合彩图库.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 老澳门六合彩图库 (老澳门六合彩图库) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 老澳门六合彩图库 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 老澳门六合彩图库’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.